• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种早期识别抗抑郁药物无反应者的实用方法。

A practical approach to the early identification of antidepressant medication non-responders.

作者信息

Li J, Kuk A Y C, Rush A J

机构信息

Department of Statistics and Applied Probability, National University of Singapore, Singapore.

Duke-National University of Singapore, Graduate Medical School, Singapore.

出版信息

Psychol Med. 2012 Feb;42(2):309-16. doi: 10.1017/S0033291711001280. Epub 2011 Jul 25.

DOI:10.1017/S0033291711001280
PMID:21781376
Abstract

BACKGROUND

The aim of the present study was to determine whether a combination of baseline features and early post-baseline depressive symptom changes have clinical value in predicting out-patient non-response in depressed out-patients after 8 weeks of medication treatment.

METHOD

We analysed data from the Combining Medications to Enhance Depression Outcomes study for 447 participants with complete 16-item Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR16) ratings at baseline and at treatment weeks 2, 4 and 8. We used a multi-time point, recursive subsetting approach that included baseline features and changes in QIDS-SR16 scores from baseline to weeks 2 and 4, to identify non-responders (<50% reduction in QIDS-SR16) at week 8 with a pre-specified accuracy level.

RESULTS

Pretreatment clinical features alone were not clinically useful predictors of non-response after 8 weeks of treatment. Baseline to week 2 symptom change identified 48 non-responders (of which 36 were true non-responders). This approach gave a clinically meaningful negative predictive value of 0.75. Symptom change from baseline to week 4 identified 79 non-responders (of which 60 were true non-responders), achieving the same accuracy. Symptom change at both weeks 2 and 4 identified 87 participants (almost 20% of the sample) as non-responders with the same accuracy. More participants with chronic than non-chronic index episodes could be accurately identified by week 4.

CONCLUSIONS

Specific baseline clinical features combined with symptom changes by weeks 2-4 can provide clinically actionable results, enhancing the efficiency of care by personalizing the treatment of depression.

摘要

背景

本研究的目的是确定基线特征与基线后早期抑郁症状变化的组合在预测药物治疗8周后门诊抑郁症患者无反应方面是否具有临床价值。

方法

我们分析了“联合用药改善抑郁结局”研究中的数据,该研究涉及447名参与者,他们在基线以及治疗第2、4和8周时完成了16项抑郁症状快速自评量表(QIDS-SR16)评分。我们采用多时间点递归子集法,该方法纳入基线特征以及从基线到第2周和第4周QIDS-SR16评分的变化,以在预先设定的准确度水平下识别第8周时的无反应者(QIDS-SR16评分降低<50%)。

结果

仅治疗前临床特征在预测治疗8周后无反应方面并无临床实用价值。从基线到第2周的症状变化识别出48名无反应者(其中36名是真正的无反应者)。这种方法得出的临床意义上的阴性预测值为0.75。从基线到第4周的症状变化识别出79名无反应者(其中60名是真正的无反应者),准确度相同。第2周和第4周的症状变化均识别出87名参与者(几乎占样本的20%)为无反应者,准确度相同。到第4周时,可以更准确地识别出更多患有慢性而非非慢性索引发作的参与者。

结论

特定的基线临床特征与第2至4周的症状变化相结合可提供具有临床可操作性的结果,通过使抑郁症治疗个性化提高护理效率。

相似文献

1
A practical approach to the early identification of antidepressant medication non-responders.一种早期识别抗抑郁药物无反应者的实用方法。
Psychol Med. 2012 Feb;42(2):309-16. doi: 10.1017/S0033291711001280. Epub 2011 Jul 25.
2
Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care.递归子集法识别 STAR*D 患者:提高治疗结果早期预测准确性并为个体化治疗提供信息的方法。
J Clin Psychiatry. 2010 Nov;71(11):1502-8. doi: 10.4088/JCP.10m06168blu.
3
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.自我报告的抑郁症状测量:在慢性抑郁、非精神病性门诊患者的随机对照试验中检测变化的敏感性。
Neuropsychopharmacology. 2005 Feb;30(2):405-16. doi: 10.1038/sj.npp.1300614.
4
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.激惹及其在重性抑郁障碍中的临床应用:使用激惹和抑郁严重程度的早期变化预测个体急性期结局。
Am J Psychiatry. 2019 May 1;176(5):358-366. doi: 10.1176/appi.ajp.2018.18030355. Epub 2019 Mar 29.
5
Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.抗抑郁药治疗对随机试验中自杀意念和行为的影响:来自联合用药以增强抑郁结局研究的探索性报告。
J Clin Psychiatry. 2011 Oct;72(10):1322-32. doi: 10.4088/JCP.10m06724.
6
Clinical features and drug induced side effects in early versus late antidepressant responders.早期和晚期抗抑郁药应答者的临床特征和药物诱导的副作用。
J Psychiatr Res. 2013 Oct;47(10):1309-18. doi: 10.1016/j.jpsychires.2013.05.020. Epub 2013 Jun 22.
7
Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.既往疾病史与抑郁门诊患者的急性或长期结局相关吗?一项 STAR*D 报告。
Psychol Med. 2012 Jun;42(6):1131-49. doi: 10.1017/S0033291711002170. Epub 2011 Oct 19.
8
A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder.基于地点的评估与集中评估以及患者自评在重性抑郁障碍临床试验中的比较分析。
J Psychiatr Res. 2013 Jul;47(7):944-54. doi: 10.1016/j.jpsychires.2013.02.016. Epub 2013 Apr 4.
9
Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.舍曲林治疗初始治疗帕罗西汀或氟伏沙明失败的重性抑郁障碍患者。
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):223-7. doi: 10.1016/j.pnpbp.2012.04.001. Epub 2012 Apr 5.
10
Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.抗抑郁药引发的早期改善能否预测疗效/缓解情况?对大量重度抑郁症住院患者的自然主义研究数据进行分析。
J Affect Disord. 2009 Jun;115(3):439-49. doi: 10.1016/j.jad.2008.10.011. Epub 2008 Nov 22.

引用本文的文献

1
Performance of diagnostic tests based on continuous bivariate markers.基于连续双变量标志物的诊断试验性能
J Appl Stat. 2022 Oct 26;51(3):497-514. doi: 10.1080/02664763.2022.2137478. eCollection 2024.
2
A Clinician's Perspective on Biomarkers.临床医生对生物标志物的看法。
Focus (Am Psychiatr Publ). 2018 Apr;16(2):124-134. doi: 10.1176/appi.focus.20170044. Epub 2018 Apr 27.
3
Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials.
基于症状测量增加单一活动障碍指标预测急性期治疗结局:来自 STAR*D 和 CO-MED 试验的交互式计算器的开发和验证。
Int J Neuropsychopharmacol. 2019 May 1;22(5):339-348. doi: 10.1093/ijnp/pyz011.
4
Accurately identifying patients who are excellent candidates or unsuitable for a medication: a novel approach.准确识别适合或不适合某种药物治疗的患者:一种新方法。
Neuropsychiatr Dis Treat. 2017 Dec 15;13:3001-3010. doi: 10.2147/NDT.S139577. eCollection 2017.
5
Is the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?重度抑郁发作的早期反应能否预测最终治疗反应?
Noro Psikiyatr Ars. 2016 Sep;53(3):245-252. doi: 10.5152/npa.2015.10141. Epub 2016 Sep 1.
6
Targeting treatments for depression: what can our patients tell us?抑郁症的靶向治疗:我们的患者能告诉我们什么?
Epidemiol Psychiatr Sci. 2017 Feb;26(1):37-39. doi: 10.1017/S2045796016000160. Epub 2016 Apr 5.
7
Toward an online cognitive and emotional battery to predict treatment remission in depression.迈向用于预测抑郁症治疗缓解情况的在线认知与情感测试组合。
Neuropsychiatr Dis Treat. 2015 Feb 26;11:517-31. doi: 10.2147/NDT.S75975. eCollection 2015.
8
An update on antidepressant use in bipolar depression.双相抑郁障碍中抗抑郁药使用的最新进展。
Curr Psychiatry Rep. 2012 Dec;14(6):696-704. doi: 10.1007/s11920-012-0323-6.
9
Personalized medicine in major depressive disorder -- opportunities and pitfalls.重度抑郁症的个性化医学——机遇与陷阱。
Metabolism. 2013 Jan;62 Suppl 1(0 1):S34-9. doi: 10.1016/j.metabol.2012.08.021. Epub 2012 Sep 26.